FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130230977> ?p ?o ?g. }

• W2130230977 endingPage "e6434" @default.
• W2130230977 startingPage "e6434" @default.
• W2130230977 abstract "Background The constant increase of cancer cell resistance to radio- and chemotherapy hampers improvement of patient survival and requires novel targeting approaches. Integrin-Linked Kinase (ILK) has been postulated as potent druggable cancer target. On the basis of our previous findings clearly showing that ILK transduces antisurvival signals in cells exposed to ionizing radiation, this study evaluated the impact of the small molecule inhibitor QLT0267, reported as putative ILK inhibitor, on the cellular radiation survival response of human head and neck squamous cell carcinoma cells (hHNSCC). Methodology/Principal Findings Parental FaDu cells and FaDu cells stably transfected with a constitutively active ILK mutant (FaDu-IH) or empty vectors, UTSCC45 cells, ILKfloxed/floxed(fl/fl) and ILK−/− mouse fibroblasts were used. Cells grew either two-dimensionally (2D) on or three-dimensionally (3D) in laminin-rich extracellular matrix. Cells were treated with QLT0267 alone or in combination with irradiation (X-rays, 0–6 Gy single dose). ILK knockdown was achieved by small interfering RNA transfection. ILK kinase activity, clonogenic survival, number of residual DNA double strand breaks (rDSB; γH2AX/53BP1 foci assay), cell cycle distribution, protein expression and phosphorylation (e.g. Akt, p44/42 mitogen-activated protein kinase (MAPK)) were measured. Data on ILK kinase activity and phosphorylation of Akt and p44/42 MAPK revealed a broad inhibitory spectrum of QLT0267 without specificity for ILK. QLT0267 significantly reduced basal cell survival and enhanced the radiosensitivity of FaDu and UTSCC45 cells in a time- and concentration-dependent manner. QLT0267 exerted differential, cell culture model-dependent effects with regard to radiogenic rDSB and accumulation of cells in the G2 cell cycle phase. Relative to corresponding controls, FaDu-IH and ILKfl/fl fibroblasts showed enhanced radiosensitivity, which failed to be antagonized by QLT0267. A knockdown of ILK revealed no change in clonogenic survival of the tested cell lines as compared to controls. Conclusions/Significance Our data clearly show that the small molecule inhibitor QLT0267 has potent cytotoxic and radiosensitizing capability in hHNSCC cells. However, QLT0267 is not specific for ILK. Further in vitro and in vivo studies are necessary to clarify the potential of QLT0267 as a targeted therapeutic in the clinic." @default.
• W2130230977 created "2016-06-24" @default.
• W2130230977 creator A5024834411 @default.
• W2130230977 creator A5039794800 @default.
• W2130230977 creator A5071952943 @default.
• W2130230977 creator A5072871907 @default.
• W2130230977 creator A5075388083 @default.
• W2130230977 date "2009-07-30" @default.
• W2130230977 modified "2023-10-18" @default.
• W2130230977 title "The Small Molecule Inhibitor QLT0267 Radiosensitizes Squamous Cell Carcinoma Cells of the Head and Neck" @default.
• W2130230977 cites W1528621722 @default.
• W2130230977 cites W1600844927 @default.
• W2130230977 cites W1967293289 @default.
• W2130230977 cites W1968461830 @default.
• W2130230977 cites W1971045882 @default.
• W2130230977 cites W1985292397 @default.
• W2130230977 cites W1988588903 @default.
• W2130230977 cites W1991083835 @default.
• W2130230977 cites W1992925170 @default.
• W2130230977 cites W1997203401 @default.
• W2130230977 cites W2000096403 @default.
• W2130230977 cites W2004806132 @default.
• W2130230977 cites W2010594589 @default.
• W2130230977 cites W2016086822 @default.
• W2130230977 cites W2019219567 @default.
• W2130230977 cites W2020850126 @default.
• W2130230977 cites W2027000221 @default.
• W2130230977 cites W2029583894 @default.
• W2130230977 cites W2038468856 @default.
• W2130230977 cites W2041444090 @default.
• W2130230977 cites W2045027538 @default.
• W2130230977 cites W2050108686 @default.
• W2130230977 cites W2053591860 @default.
• W2130230977 cites W2060136332 @default.
• W2130230977 cites W2062513341 @default.
• W2130230977 cites W2069427120 @default.
• W2130230977 cites W2080487750 @default.
• W2130230977 cites W2087472895 @default.
• W2130230977 cites W2096354011 @default.
• W2130230977 cites W2098033797 @default.
• W2130230977 cites W2118493809 @default.
• W2130230977 cites W2118719170 @default.
• W2130230977 cites W2127362646 @default.
• W2130230977 cites W2147887967 @default.
• W2130230977 cites W2151041025 @default.
• W2130230977 cites W2151881633 @default.
• W2130230977 cites W2155384808 @default.
• W2130230977 cites W2159492594 @default.
• W2130230977 cites W2162388985 @default.
• W2130230977 cites W2167033631 @default.
• W2130230977 cites W2325413783 @default.
• W2130230977 cites W2326916312 @default.
• W2130230977 doi "https://doi.org/10.1371/journal.pone.0006434" @default.
• W2130230977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2713401" @default.
• W2130230977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19649326" @default.
• W2130230977 hasPublicationYear "2009" @default.
• W2130230977 type Work @default.
• W2130230977 sameAs 2130230977 @default.
• W2130230977 citedByCount "54" @default.
• W2130230977 countsByYear W21302309772012 @default.
• W2130230977 countsByYear W21302309772013 @default.
• W2130230977 countsByYear W21302309772014 @default.
• W2130230977 countsByYear W21302309772015 @default.
• W2130230977 countsByYear W21302309772016 @default.
• W2130230977 countsByYear W21302309772017 @default.
• W2130230977 countsByYear W21302309772018 @default.
• W2130230977 countsByYear W21302309772019 @default.
• W2130230977 countsByYear W21302309772020 @default.
• W2130230977 countsByYear W21302309772021 @default.
• W2130230977 countsByYear W21302309772022 @default.
• W2130230977 countsByYear W21302309772023 @default.
• W2130230977 crossrefType "journal-article" @default.
• W2130230977 hasAuthorship W2130230977A5024834411 @default.
• W2130230977 hasAuthorship W2130230977A5039794800 @default.
• W2130230977 hasAuthorship W2130230977A5071952943 @default.
• W2130230977 hasAuthorship W2130230977A5072871907 @default.
• W2130230977 hasAuthorship W2130230977A5075388083 @default.
• W2130230977 hasBestOaLocation W21302309771 @default.
• W2130230977 hasConcept C11960822 @default.
• W2130230977 hasConcept C126322002 @default.
• W2130230977 hasConcept C1491633281 @default.
• W2130230977 hasConcept C153911025 @default.
• W2130230977 hasConcept C184235292 @default.
• W2130230977 hasConcept C185592680 @default.
• W2130230977 hasConcept C206684579 @default.
• W2130230977 hasConcept C29537977 @default.
• W2130230977 hasConcept C502942594 @default.
• W2130230977 hasConcept C509974204 @default.
• W2130230977 hasConcept C54009773 @default.
• W2130230977 hasConcept C54355233 @default.
• W2130230977 hasConcept C55493867 @default.
• W2130230977 hasConcept C58962609 @default.
• W2130230977 hasConcept C66417403 @default.
• W2130230977 hasConcept C71924100 @default.
• W2130230977 hasConcept C75217442 @default.
• W2130230977 hasConcept C81885089 @default.
• W2130230977 hasConcept C82495950 @default.
• W2130230977 hasConcept C86803240 @default.

• next